Lactic Acid, Citric Acid, and Potassium Bitartrate
Medically reviewed by Drugs.com. Last updated on Feb 18, 2020.
(LAK tik AS id, SIT rik AS id & poe TAS ee um bye TAR trate)
- Citric Acid, Lactic Acid, and Potassium Bitartrate
- Citric Acid, Potassium Bitartrate, and Lactic Acid
- Lactic Acid, Potassium Bitartrate, and Citric Acid
- Potassium Bitartrate, Citric Acid, and Lactic Acid
- Potassium Bitartrate, Lactic Acid, and Citric Acid
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Phexxi: Lactic acid 1.8%, citric acid 1%, and potassium bitartrate 0.4% (5 g) [contains benzoic acid]
Brand Names: U.S.
Following vaginal application, the combination of lactic acid, citric acid, and potassium bitartrate maintains vaginal pH in an acidic range and decreases sperm motility. In addition to providing rapidly reversible contraception, this product has also been evaluated for lubricant and antimicrobial properties (Nelson 2018).
Not systemically absorbed (Nelson 2018).
Use: Labeled Indications
Contraception: Prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
Limitations of use: Not effective for the prevention of pregnancy when administered after intercourse.
There are no contraindications listed in the manufacturer's labeling.
Contraception: Intravaginal: Insert the contents of 1 prefilled applicator vaginally immediately before or up to 1 hour before each act of vaginal intercourse. An additional dose is needed if vaginal intercourse does not occur within 1 hour of insertion. One application is needed for each act of vaginal intercourse; if more than 1 act of vaginal intercourse occurs within 1 hour, additional doses must be applied.
For use in women of reproductive potential; not for use in postmenopausal women.
Contraception: Postmenarche females: Intravaginal: 1 prefilled applicator (5 g) immediately before or up to 1 hour before each act of vaginal intercourse; repeat dose if vaginal intercourse does not occur within 1 hour of administration; an additional dose is needed if >1 act of vaginal intercourse occurs within 1 hour. Note: Not effective for the prevention of pregnancy when administered after vaginal intercourse.
Intravaginal: For vaginal administration only. May be used at any time during the menstrual cycle. May be used following childbirth, abortion, or miscarriage once vaginal intercourse is safe to resume. Avoid use with vaginal rings. May be used concomitantly with hormonal contraceptives, condoms (latex, polyurethane, and polyisoprene), and vaginal diaphragms. May be used concomitantly with products for vaginal infections (including miconazole, metronidazole, or tioconazole).
Store in original foil pack at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
Ethinyl Estradiol: May diminish the therapeutic effect of Lactic Acid, Citric Acid, and Potassium Bitartrate. Avoid combination
>10%: Genitourinary: Vulvovaginal burning (18%), vulvovaginal pruritus (15%)
1% to 10%:
Genitourinary: Bacterial vaginosis (8%), dysuria (3%), urinary tract infection (9%), vaginal discharge (6%), vaginal discomfort (9%), vaginal pain (2%), vulvar pain (genital discomfort: 4%), vulvovaginal candidiasis (9%)
Nervous system: Local discomfort (male partners: 10%; burning, itching, pain [mild: 75%, moderate: 20%, severe: 4%])
Hypersensitivity: Hypersensitivity reaction
Concerns related to adverse effects:
• Genitourinary effects: Avoid use in females with a history of recurrent urinary tract infections (UTIs) or urinary tract abnormalities; use may increase risk of UTIs. Cystitis, upper UTIs, and pyelonephritis (requiring hospitalization in one case) have been reported.
• Vulvovaginal effects: Burning and pruritus may occur; effects are usually mild but may require discontinuation in some cases.
• Pediatric: Not for use prior to menarche.
• Postmenopausal women: Not indicated for use in postmenopausal women.
• HIV infection protection: Use of this product does not protect against HIV infection or other sexually transmitted diseases.
Local hypersensitivity reactions; signs of urinary tract infection.
This product is a nonhormonal contraceptive, intended to prevent pregnancy when used immediately prior to or up to 1 hour prior to vaginal intercourse. It may be used at any time during the menstrual cycle, and after childbirth, abortion, or miscarriage once it is safe to resume vaginal intercourse. It is not effective for contraception after vaginal intercourse.
Avoid use with vaginal rings. May be used concomitantly with hormonal contraceptives, condoms (latex, polyurethane, and polyisoprene), and vaginal diaphragms.
In a premarketing study, the cumulative pregnancy rate was 13.7% (95% CI: 10% to 17.5%) over 7 cycles of typical use.
Male partners may experience local discomfort (eg, burning, itching, pain); symptoms are most commonly mild to moderate in severity.
This product is intended to prevent pregnancy; it should not be used if pregnancy is confirmed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.